The stock of Silence Therapeutics Plc ADR (SLN) has gone down by -24.57% for the week, with a -48.34% drop in the past month and a -67.56% drop in the past quarter. The volatility ratio for the week is 19.01%, and the volatility levels for the past 30 days are 13.77% for SLN. The simple moving average for the past 20 days is -32.52% for SLN’s stock, with a -82.01% simple moving average for the past 200 days.
Is It Worth Investing in Silence Therapeutics Plc ADR (NASDAQ: SLN) Right Now?
The 36-month beta value for SLN is at 1.27. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLN is 37.56M, and currently, shorts hold a 3.75% of that float. The average trading volume for SLN on April 10, 2025 was 286.72K shares.
SLN) stock’s latest price update
The stock price of Silence Therapeutics Plc ADR (NASDAQ: SLN) has dropped by -5.22 compared to previous close of 2.30. Despite this, the company has seen a fall of -24.57% in its stock price over the last five trading days. businesswire.com reported 2025-03-05 that LONDON–(BUSINESS WIRE)—- $SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be.
Analysts’ Opinion of SLN
Many brokerage firms have already submitted their reports for SLN stocks, with Goldman repeating the rating for SLN by listing it as a “Sell.” The predicted price for SLN in the upcoming period, according to Goldman is $6 based on the research report published on February 11, 2025 of the current year 2025.
Jefferies gave a rating of “Buy” to SLN, setting the target price at $40 in the report published on September 03rd of the previous year.
SLN Trading at -48.05% from the 50-Day Moving Average
After a stumble in the market that brought SLN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.06% of loss for the given period.
Volatility was left at 13.77%, however, over the last 30 days, the volatility rate increased by 19.01%, as shares sank -48.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -59.18% lower at present.
During the last 5 trading sessions, SLN fell by -24.57%, which changed the moving average for the period of 200-days by -88.91% in comparison to the 20-day moving average, which settled at $3.23. In addition, Silence Therapeutics Plc ADR saw -68.31% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLN
Current profitability levels for the company are sitting at:
- -1.25 for the present operating margin
- 0.76 for the gross margin
The net margin for Silence Therapeutics Plc ADR stands at -0.79. The total capital return value is set at -0.26. Equity return is now at value -99.23, with -43.26 for asset returns.
Based on Silence Therapeutics Plc ADR (SLN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -550.26. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 17.51.
Currently, EBITDA for the company is -48.99 million with net debt to EBITDA at 3.42. When we switch over and look at the enterprise to sales, we see a ratio of -1.06. The receivables turnover for the company is 1.43for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.31.
Conclusion
In conclusion, Silence Therapeutics Plc ADR (SLN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
